[Study on early predictive factors of an incomplete viral response with 48 week-entecavir therapy in HBeAg-positive chronic hepatitis B patients] [0.03%]
乙型肝炎e抗原阳性慢性乙肝患者48周恩替卡韦治疗无病毒学应答的早期预测因素研究
Z F Zhou,Y Ding,C Zhang et al.
Z F Zhou et al.
Objective: To study the virological and serological indicators before treatment and 24 weeks after treatment to predict the partial virological response (PVR) of 48-week entecavir (ETV) treatment, and formulate early clinical adjustment tre...
[Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)] [0.03%]
肝硬化门静脉血栓形成管理专家共识 (2020 上海)
Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association
Hepatobiliary Disease Study Group
[Risk factors associated with the progression of chronic HBV infection in patients with normal ALT] [0.03%]
正常ALT水平慢性乙型肝炎病毒感染进展的危险因素研究
L Wei,H Li,P Hu
L Wei
Hepatitis B virus (HBV) infection is one of the common causes of chronic hepatitis in China. Active antiviral therapy can effectively reduce the occurrence risk of end-stage liver diseases, such as decompensated cirrhosis, liver failure and...
[Assessing the relationship between ALT level with disease progression and treatment timing] [0.03%]
评估ALT水平与疾病进展及治疗时机的关系
X E Liang,J Sun
X E Liang
Serum alanine aminotransferase (ALT) is a sensitive and important marker of liver injury, which is closely related to the disease progression. It is the key rather than the only parameter to initiate treatment decisions for patients with ch...
[Optimal timing of antiviral therapy for chronic HBV-infected patients with normal ALT] [0.03%]
正常ALT水平的慢性HBV感染患者抗病毒治疗的最佳时机
H L Gui,Q Xie
H L Gui
Whether to initiate antiviral therapy in chronic hepatitis B virus (HBV) infected population with normal alanine aminotransferase (ALT) is hot and difficult issue. Improvements in drug availability and affordability have paved the way for m...
[Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT] [0.03%]
慢性乙型肝炎正常ALT水平患者治疗的优化时机及其临床意义
Y X Fan,X G Dou
Y X Fan
Due to the difference in infection time and immune clearance ability, patients with chronic hepatitis B virus (HBV) infection may appear as virus carrier or chronic active hepatitis. Alanine aminotransferase (ALT) is the most sensitive biom...
[The mechanisms of the translation of polymerase from HBV pregenomic RNA] [0.03%]
乙肝病毒前基因组RNA聚合酶转移的机制
D J Lu,H L Zheng,J Y Xi et al.
D J Lu et al.
Hepatitis B virus (HBV) is an important pathogen that causes different liver diseases such as viral hepatitis and liver cirrhosis. HBV pregenomic RNA (pgRNA) plays a crucial role in HBV life cycle, which is not only the translation template...
[Regulatory effect of molecular targeted drugs on the immune system for liver cancer] [0.03%]
分子靶向药物对肝癌免疫系统的影响机制
X Cheng,J Z Chen,Y B Guo
X Cheng
Molecular targeted drugs are the first choice for systemic treatment of liver cancer. In the past decade, several anti-liver cancer targeted drugs have been launched. More recently, immunotherapy has become a dazzling nova in the field of s...
[Susceptibility factors, types and management of infection in patients with liver cirrhosis] [0.03%]
肝硬化患者感染的易感因素、类型及处理
J Qiao,R Q Wang,Y M Nan
J Qiao
Patients with liver cirrhosis are prone to infection due to various reasons such as weakened immunity and intestinal bacteria translocation. Among them, bacterial infections are the most common and are the main cause for liver failure progr...
G Q Xiang,F R Sun,B Y Wang
G Q Xiang
Gilbert's syndrome is a kind of benign inherited disease of bilirubin binding disorder, mainly due to the homozygous polymorphism A(TA)7TAA in the promoter of the gene for uridine diphosphate -glucuronosyltransferase 1A1 (UGT1A1), which is ...